Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 4/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.43 |
| ▸ | FEN1 | P39748 | 3/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514677 | 0.92 | TNF (0.49) | TNFMETMKNK1MKNK2PIK3CA | |
| SCHEMBL3514354 | 0.90 | PIK3CA (0.51) | TNFMKNK1MKNK2PIK3CALRRK2 | |
| SCHEMBL3514839 | 0.90 | TNF (0.47) | TNFMETMKNK1MKNK2PIK3CA | |
| SCHEMBL3516131 | 0.89 | MKNK1 (0.55) | TNFMKNK1MKNK2PIK3CACAMK2D | |
| SCHEMBL3514542 | 0.88 | IKBKB (0.53) | TNFMETPIK3CACAMK2DPIM1 | |
| SCHEMBL3512904 | 0.87 | TNF (0.47) | TNF | |
| SCHEMBL3513489 | 0.87 | IKBKB (0.48) | TNFMKNK1MKNK2PIK3CACAMK2D | |
| SCHEMBL3515819 | 0.85 | TNF (0.49) | TNFMETPIK3CAPARP1 | |
| SCHEMBL3514196 | 0.85 | TNF (0.45) | TNFMKNK1MKNK2PIK3CAPARP1 | |
| SCHEMBL3514853 | 0.83 | PIK3CA (0.48) | TNFMKNK1MKNK2PIK3CALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | claimed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | TNF 1981/4885MET 2000/4885MKNK1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.